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INTRODUCTION Forced Expiratory Volume in first second (FEV ): 1
  This  is  the  maximal  volume  of  gas  which  can  be  expired 
  The  assessment  of  pulmonary  function  is  now  a  from  the  lung  in  the  first  second  of  a  forced  expiration 
routine  part  of  clinical  practice.  Pulmonary  from a position of full inspiration.
function  test  is  done  to  evaluate  the  following 
conditions: Forced Vital capacity (FVC): 
This  is  the  maximum  volume  of  gas  which  can  be  expired 
1. To define the asthma. from  the  lungs  during  a  forced  expiration  from  a  position 
2. To  assess  the  severity  of  Bronchial  of full inspiration.
Asthma.
3. To  establish  the  bronchodilator  drug  Forced Vital Ratio (FVR):
response before and after treatment ,   It  is  the  ratio  of  FEV /FVC.  This  is  main  index  to  1
4. To  assess  the    immediate  response  to  differentiate  restricted  lung  disease  from  bronchial 
bronchodilator drug. asthma. In obstructive disease the FEV /FVC is decreased  1
5. To  assess  the  gradual  progression  or  below  75%,  where  as  in  restricted  lung  diseases  it  is 
regression of the disease over the years. normal or increased.
6. To  assess  the  recovery  from  severe 
asthmatic attack. Peak Expiratory Flow Rate (PEFR):
The  guidelines  for  PFT  were  recently  carried  out  It  is  defined  as  the  maximum  flow  achievable  from  a 
by  the  Association  of  Respiratory  Technicians  forced  expiration  starting  at  full  inspiration  with  an  open 
Society  and  ARTP  Liaison  Committee,  the  main  glottis.
functions  which  can  be  done  include  1)  Lung  The  highest  reading  of  three  acceptable  blows  should  be 
volume  2)  Diffusion  capacity  3)  Expiratory  flow  recorded.  The  diurnal  variations  of  the  peak  expiratory 
rates and 4) Bronchodilator drug response. flow rate and forced expiratory volume in 1 second should 
The  expiratory  flow  rates  may  be  assessed  by  be noted.
Spirogram  or  by  Electronic  device,  Microplus 
spirometer.
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ABSTRACT
Tamaka  Shvasa  which  has  been  mentioned  in  Ayurvedic  classics  shares  multiple 
similarities with Bronchial Asthma. Symptom of breathlessness is the main complaint in 
Bronchial  Asthma  which  can  be  assessed  objectively  by  Pulmonary  Function  Test 
(PFT).The  assessment  of  respiratory  function  is  now  a  routine  part  of  clinical 
practice.The  expiratory  flow  rates-  Forced  Expiratory  Volume  in  first  second  (FEV ),  1
Forced  Vital  Capacity  (FVC)  and  Peak  Expiratory  Flow  Rate  (PEFR)  are  assessed  by 
an  Electronic  Spirometer  (Kent,  England).  Six  weeks  treatment  with  a  compound 
preparation  of    herbs    including  -  Sati  (Hedichum  spicatum,  Rose),  Puskaramoola 
(Innula  racemosa,  Linn),  and  Amalaki  (Emblica  officinalis,Gaertn)  powder  showed  a 
significant effect of increase in Pulmonary Function values .The mean grade score plus 
standard  deviation  before  trial    of  FEV,  FVC,  and  PEFR  were  62.6±15.06,  2.03±o.53 
and 189±44.05 respectively. After six weeks of treatment with Puskaramooladi choorna 
FEV,  FVC  and  PEFR  showed  highly  significant  results  with  values  63.45±15.9, 
2.81±0.33 and 199.6±41.58 respectively. Puskaramooladi choorna can be used as one 
of the potent medicine in the treatment of the Bronchial Asthma.
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MATERIALS AND METHODS Positive 24(69.6%)
Negative                                            11(31.45%)
Thirty  five  patients  having  Bronchial  Asthma  were 
Duration of illness (in years) 6.18± 6.02 randomly  selected  from  the  O.P.D.  and  I.P.D.  of 
S.S.Hospital, Banaras Hindu University and diagnosed 
Previous  medication on  the  basis  of  detailed  questionnaire  along  the 
Salbutamol  28(80.0%) symptom  of  breathlessness,  wheezing,  paroxysmal 
Theophylline 10(28.4%) cough,  with  or  without  expectoration  and  family 
Cortisone 19(54.2%) history of allergy. Informed consent was obtained from 
patients.Twenty  five  patients  were  treated  with 
Nature  of  attack Puskaramooladi choorna and ten patients were treated 
Seasonal                                              24 (68.5%) with Theophylline tablet. (Sustained release 400 mg).
Irregular                                                8(22.8%) Objective criteria for diagnosis:
Continues 4(14.2%) Pulmonary  function  test:    Spirometric  test  was  done 
Respiratory  rate                                                                      34.31±8.24 with  the  Electronic  Microplus  Spirometer, 
Pulse rate 8.74± 2.16 Micromedical  Ltd.,  Rochester,  Kent,  England.  FEV ,  1
Blood  picture                                                                          Mean  ±S.D. FVC, FVR and PEFR were recorded. Averages of three 
  readings  were  taken.  FEV   percentage  was  calculated  1
TLC8625±1690 from  predicted  values  mentioned  in  Spirometric 
Neutrophils                                                                                   61.2     ± 7.5 calculator  based  on  patients,  age,  height  and  weight. 
Lymphocytes 30.6 ± 9.6 FVC  and  PEFR  were  calculated.  The  pulmonary 
Monocytes                                                                               0.428     ±0.69 impairment  was  assessed  by  criteria  based  on  the 
Eosinophilis 6.65 ±5.74 recommendation of the American Thoracic Society
Absolute Eosinophil Count                                 558.9 ± 469. Laboratory investigations:
Hemoglobin (gm) 11.2 ±1.05 I. Blood  examination:  TLC,  DLC,  AEC 
Erythrocyte Sedimentation Rate             15.17 ±10.88 (Absolute Eosinophil Count).
II. Sputum:  For  AFB  and  Culture  for 
Pulmonary  Function  Test microorganisms.
FEV  (%) 61.89 ±13.18 1                                                                                   III. ECG: to exclude cardiac diseases.
FVC (lts/min)                                                                             2.00 ±0.49
PEFR  (lts/min)                                                    19994.4      ±  51.32. Clinical profile of the patients registered for trial.
Preparation  of  Drug  and  Mode  of Administration Profile                                                                                                 value
As  per  the  reference  in  Caraka  samhita,Chikitsa  Mean Age  34.3±17.46
Sthana,Chapter  18,  verse  129,  equal  parts  of  roots  of 
Puskara,  rhizomes  of  Sati  and  the  fruits  of  Amalaki  Sex
after  removal  of  the  seeds  were  finely    powdered.  The  Male                                                                                                      24(68.57%)
Raw  Drugs  were  collected  from  the  market  and  Female                                                                                                11(22.43%)
verified  for  authentication  by  the  department  of 
Dravyaguna, Faculty of Ayurveda, IMS, BHU. Habitat
Nine  grams  of  the  powder  were  given  in  3  divided  Urban                                             23(65.71%)
doses  with  honey.  The  effect  of  the  drug  was  assessed  Rural                                             12(34.28%)
fortnightly for a period of 6 weeks.
Parameters for Assessment: Diet
Objective parameters: Vegetarian 13(37.4%)
    Forced  Expiratory  Volume  in  first  second  Non   vegetarian 22(62.8%)
(FEV ). 1
Family  history  Forced Vital Capacity (FVC).
Of  bronchial  asthma  Forced Vital Ratio (FVR).
Positive                                               11(31.45)  Peak Expiratory Flow Rate (PEFR).
Negative                                              24(69.6%)  Respiratory Rate (RR).
A  Clinical  Study  on  the  use  of  Puskara  Mooladi  Choorna  in  Tamaka  Shvasa  (Bronchial Asthma)  with  Pulmonary 
Function  Tests 2
Test  Normal  Mild  Moderate  severe 
FEV1  >80  %  61-80  50-60  <50 
FVC  >80  %  61-80  50-60  <50 
PEFR  >80  %  61-80  50-60  <50 
 
Table  1:  Spirometric  criteria  for  assessing  pulmonary  impairment 
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RESULTS 
Table  2:  Response  of  Puskaramooladi  choorna  and  Theophylline 
On  Forced  Expiratory  Volume  in  one  second  (FEV1). 
 
Puskaramooladi  choorna  (n=25)  Theophylline(n=10) 
M.G.S.  ±  S.D  S.E.  t(p)  M.G.S.  ±  S.D  S.E.  t(p) 
BT  62    ±  15.06  3.01    60.9      ±  6.36  2.015   
AT1  62.81    ±  15.3  33.07    63.4    ±    6.86  2.17   
D1  0.68    ±  1.55  0.36  1.88(>0.05)  2.7  ±    3.17  0.99  2.72(<0.01) 
AT2  63.06    ±  15.78  3.15    64.1  ±    6.55  2.07   
D2  1.032    ±    2.29  0.458  2.25(<0.05)  3.4  ±    3.02  0.95  3.5(<0.001) 
AT3  63.45    ±  15.91  3.18    65.0  ±    6.01  1.90   
d3  1.7    ±  2.06  0.412  3.09(<0.001)  4.0    ±  2.82  0.89  4.49(0.001) 
 
Table  3:  Response  of  Puskaramooladi  choorna  and  Theophylline 
On  Forced  Vital  Capacity  (FVC). 
 
Puskaramooladi  choorna  (n=25)  Theophylline(n=10) 
M.G.S.  ±  S.D  S.E.  t(p)  M.G.S.  ±  S.D  S.E.  t(p) 
BT  2.3  ±  0.53  0.10    2.05    ±  0.21  2.015   
AT1  2.19    ±  0.37  0.07    2.32  ±    0.24  0.078   
D1  0.14  ±  0.347  0..06  2.02(>0.05)  0.263±    0.149  0.047  5.59(<0.01) 
AT2  2.28    ±  0.42  0.084    2.46  ±    0.23  0.07   
D2  0.22  ±    0.420  084  2.65(<0.02)  0.0407  ±    0.19  0.061  6.67(<0.001) 
AT3  2.81  ±  0.33  0.067    2.856  ±    0.16  0.032   
d3  0.30    ±  0.40  0.08  3.75(<0.01)  0.802  ±  0.166  0.052  15.4(<0.001) 
  Table  4:  Response  of  Puskaramooladi  choorna  and  Theophylline 
On  Peak  Expiratory  Flow  Rate  (PEFR). 
 
Puskaramooladi  choorna  (n=25)  Theophylline(n=10) 
M.G.S.  ±  S.D  S.E.  t(p)  M.G.S.  ±  S.D  S.E.  t(p) 
BT  189.04±44.03  8.81    207.9  ±  67.03  2.12   
AT1  195.16±  42.2  8.45    215.4  ±    62.2  19.69   
D1  6.28  ±  11.75  2.35  2.67(>0.02)  6.9±    6.1  1.95  3.5(<0.001) 
AT2  196.48    ±  43.0  8.6    219.6  ±    60.6  18.9   
D2  8.0  ±    10.5  2.10  3.80(<0.001)  10.66  ±    9.05  2.86  3.7(<0.001) 
AT3  199.6  ±  41.5  8.31    226.9±    57.2  18.10   
d3  10.08    ±11.6  2.32  4.34(<0.001)  17.9  ±  14.6  4.48  3.99(<0.001) 
 
Table  5:    Response  of  Puskaramooladi  choorna  and  Theophylline 
On  Respiratory  Rate  (R.R). 
 
Puskaramooladi  choorna  (n=25)  Theophylline(n=10) 
M.G.S.  ±  S.D  S.E.  t(p)  M.G.S.  ±  S.D  S.E.  t(p) 
BT  34.28±8.00  1.60    34.4  ±  9.25  2.92   
AT1  32.84±8.64  1.72    30.1±    5.98  1.19   
D1  1.52  ±  3.57  0.71  2.14(>0.02)  4.3±    6.39  1.27  3.38(<0.001) 
AT2  32.26    ±  8.43  1.68    26.8±    5.55  1.10   
D2  2.32  ±    3.02  0.60  3.86(<0.001)  7.4  ±    5.66  1.13  6.5(<0.001) 
AT3  31.44±  8.25  1.65    25.3±    4.62  0.92   
d3  3.08  ±3.29  0.65  4.73(<0.001)  8.8  ±  5.11  1.02  8.6(<0.001) 
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BT: Before treatment; AT : After treatment of 2 weeks;  REFERENCE 1
AT : After treatment of 4 weeks; AT : After treatment of  2 3
1.  Asthanga  Hridaya:  Vidyodini  Hindi  6  weeks  of  treatment;  d :  Difference  between  before  1
Commentary  by  AtriDev  Gupta,  treatment and after treatment of 2 weeks; d : Difference  2
Chowkamba  Sanskrit  series,  Varanasi,  between before treatment and treatment of 4 weeks; d :  3 1962. Difference  between  before  treatment  and  after 
2. Behera  text  book  of  pulmonary  medicine,  treatment of 6 weeks.
J.P. Brothers, 1995. MGS: Mean Grade Score.
3.  Charaka  samhita:  English  translation  by 
Sarma  P.V.,  Chowkamba  Orientalia,  New  DISCUSSION
Delhi, 1982.
4. Chaturvedi,  G.N.  et  al.  Satyadichoorna  in  The  results  of  the  clinical  study  confirm  enhanced 
Bronchial  asthma,  M.D.  (Ay)  thesis,  effect of Puskaramooladi choorna over the Pulmonary 
Kayachikitsa, I.M.S.B.H.U., 1994. Function  Tests.  There  was  a  significant  increase  in 
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Bousquel,J.  and  Godard  ,  P(Eds),  Springer    which was increased to 2.19, 2.28, 2.81 after 2, 4, and 6 
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Bronchospasm  is  the  main  pathological  component  9. Lawrence  Martin  L.  Pulmonary  Physiology 
caused  due  to  bronchial  hyper  reactivity  which  leads  in  clinical  practice  the  essential  for  patient 
to  decrease  in  expiratory  volume.  Pulmonary  care  and  evalution.  The  CV  Mosby 
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12. Sai  Prasad  and  Upadhyaya,  B.N.  Electronic  Microplus  Spirometer.  Pulmonary  function 
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thesis,  Kayachikitsa,  I.M.S.,  B.H.U.,  immunomodulatory  action  of  Puskaramooladi 
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